Alnylam Pharmaceuticals | ALNY - Debt

Stock Price
314.80
Daily Change
-5.62 -1.75%
Monthly
-7.24%
Yearly
24.21%
Q1 Forecast
303.95

Alnylam Pharmaceuticals reported $1.31B in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Incyte USD 40.41M 855K Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Moderna USD 734M 7M Sep/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novartis USD 32.02B 615M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xencor USD 69.27M 1.34M Sep/2025